Guidance. Clarity. Direction.

Carter, DeLuca & Farrell LLP, a leader in intellectual property law, provides cost-effective services to clients from around the world, protecting innovations in a wide range of technologies.

Throughout the phases of product or brand development, we form a critical part of our clients’ development teams to provide preparation, prosecution and clearance services to maximize protection while navigating through freedom-to-operate challenges. We also provide extensive IP due diligence services and IP asset assimilation to help our clients achieve their business objectives.

Search Attorneys

Events

Sep
19 – 22
2019
27th IAKL Annual Conference AttendingCarter DeLuca Partner Chul-Woo Lee will be attending the 27th Annual International Association of Korean Lawyers (IAKL) Conference from September 19, 2019...

CAFC Update

BOARD OF REGENTS v. BOSTON SCIENTIFIC CORPORATION September 5, 2019

The University of Texas (UT) and TissueGen sued Boston Scientific for infringement of U.S. Patent Nos. 6,596,296 and 7,033,603, which are directed to implantable drug-releasing biodegradable fibers. The district court determined that venue was improper and transferred the case to the District of Delaware. UT, acting as an arm of the State of Texas, appeals the district...

The University of Texas (UT) and TissueGen sued Boston Scientific for infringement of U.S. Patent Nos. 6,596,296 and 7,033,603, which are directed to...

ALLERGAN SALES, LLC v. SANDOZ, INC. August 29, 2019

Allergan sued Appellants Sandoz and Alcon, asserting that Sandoz’s Abbreviated New Drug Application (“ANDA”) for a generic version of Allergan’s ophthalmic drug Combigan® infringes Allergan’s U.S. Patent Nos. 9,770,453, 9,907,801, and 9,907,802 relating to the topical ophthalmic use of brimonidine in combination with timolol for treatment of glaucoma or ocular hypertension. The district court found limiting a...

Allergan sued Appellants Sandoz and Alcon, asserting that Sandoz’s Abbreviated New Drug Application (“ANDA”) for a generic version of Allergan’s ophthalmic drug Combigan®...

ARTHREX, INC. v. SMITH & NEPHEW, INC. August 21, 2019

In an inter partes review, the Patent Trial and Appeal Board ruled claims 10 and 11 of Arthrex’s U.S. Patent No. 8,821,541 (relating to a surgical suture anchor used to reattach soft tissue to bone) invalid. In doing so, the Board employed different language than Smith & Nephew’s petition to explain why a person of ordinary skill in the...

In an inter partes review, the Patent Trial and Appeal Board ruled claims 10 and 11 of Arthrex’s U.S. Patent No. 8,821,541 (relating to a...